{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:05:35Z","timestamp":1782443135693,"version":"3.54.5"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.ijantimicag.2023.106887","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T12:37:15Z","timestamp":1686573435000},"page":"106887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Ceftolozane\/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity"],"prefix":"10.1016","volume":"62","author":[{"given":"Akosua A.","family":"Agyeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"L\u00f3pez-Causap\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate E.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna Deveson","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cort\u00e9s-Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Gomis-Font","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Fraile-Ribot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Figuerola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinzhi","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva R.T.","family":"Franklyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Leng","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieqiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen B.","family":"Bulitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger L.","family":"Nation","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia B.","family":"Landersdorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106887_bib0001","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3389\/fmicb.2019.00913","article-title":"Tolerance and resistance of Pseudomonas aeruginosa biofilms to antimicrobial agents\u2014how P. aeruginosa can escape antibiotics","volume":"10","author":"Ciofu","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0002","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1126\/science.288.5469.1251","article-title":"High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection","volume":"288","author":"Oliver","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0003","doi-asserted-by":"crossref","first-page":"680","DOI":"10.3390\/pathogens3030680","article-title":"Pseudomonas aeruginosa diversification during infection development in cystic fibrosis lungs\u2014a review","volume":"3","author":"Sousa","year":"2014","journal-title":"Pathogens"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0004","doi-asserted-by":"crossref","first-page":"e27842","DOI":"10.1371\/journal.pone.0027842","article-title":"Evolution and adaptation in Pseudomonas aeruginosa biofilms driven by mismatch repair system-deficient mutators","volume":"6","author":"Lujan","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0005","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ijmm.2017.07.004","article-title":"Relevance of multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis","volume":"307","author":"Stefani","year":"2017","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0006","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane\u2013tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0007","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.ijantimicag.2019.01.010","article-title":"Efficacy of ceftolozane\/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model","volume":"53","author":"Gomez-Junyent","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0008","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/jac\/dkq143","article-title":"Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1","volume":"65","author":"Riera","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0009","unstructured":"European Medicines Agency (EMA). Zerbaxa (ceftolozane\/tazobactam). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zerbaxa [accessed 18 February 2023]."},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0010","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fped.2020.00173","article-title":"Ceftolozane\/tazobactam for treating children with exacerbations of cystic fibrosis due to Pseudomonas aeruginosa: a review of available data","volume":"8","author":"Garazzino","year":"2020","journal-title":"Front Pediatr"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0011","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s40121-017-0176-8","article-title":"Time\u2013kill analysis of ceftolozane\/tazobactam efficacy against mucoid Pseudomonas aeruginosa strains from cystic fibrosis patients","volume":"6","author":"Rac","year":"2017","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0012","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02578-18","article-title":"Ceftolozane\u2013tazobactam population pharmacokinetics and dose selection for further clinical evaluation in pediatric patients with complicated urinary tract or complicated intra-abdominal infections","volume":"63","author":"Larson","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0013","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/ajhp\/zxz011","article-title":"Use of continuous infusion ceftolozane\u2013tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis","volume":"76","author":"Davis","year":"2019","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0014","doi-asserted-by":"crossref","first-page":"e00830","DOI":"10.1016\/j.idcr.2020.e00830","article-title":"Ceftolozane\/tazobactam for pulmonary exacerbation in a 63-year-old cystic fibrosis patient with renal insufficiency and an elevated MIC to Pseudomonas aeruginosa","volume":"21","author":"Romano","year":"2020","journal-title":"IDCases"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0015","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1093\/jac\/dky225","article-title":"Antibacterial effect of ceftolozane\/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection","volume":"73","author":"Noel","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0016","first-page":"269","article-title":"Mechanisms of high-level ceftolozane\/tazobactam resistance in Pseudomonas aeruginosa from a severely neutropenic patient and treatment success from synergy with tobramycin","volume":"74","author":"So","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0017","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40121-016-0141-y","article-title":"In vitro activity of ceftolozane\/tazobactam alone or with an aminoglycoside against multi-drug-resistant Pseudomonas aeruginosa from pediatric cystic fibrosis patients","volume":"6","author":"Dassner","year":"2017","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0018","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02384-17","article-title":"Efficacy of human-simulated exposures of ceftolozane\u2013tazobactam alone and in combination with amikacin or colistin against multidrug-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model","volume":"62","author":"Rico Caballero","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0019","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0021","article-title":"Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis","volume":"10","author":"Smith","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0022","series-title":"Cystic fibrosis: diagnosis and management. NICE guideline NG78","year":"2017"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0023","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2021"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0024","doi-asserted-by":"crossref","first-page":"e71001","DOI":"10.1371\/journal.pone.0071001","article-title":"Clonal dissemination, emergence of mutator lineages and antibiotic resistance evolution in Pseudomonas aeruginosa cystic fibrosis chronic lung infection","volume":"8","author":"Lopez-Causape","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0025","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1128\/AAC.00196-16","article-title":"Sequential treatment of biofilms with aztreonam and tobramycin is a novel strategy for combating Pseudomonas aeruginosa chronic respiratory infections","volume":"60","author":"Rojo-Molinero","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0026","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1038\/s41598-017-05621-5","article-title":"Evolution of the Pseudomonas aeruginosa mutational resistome in an international cystic fibrosis clone","volume":"7","author":"Lopez-Causape","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0027","first-page":"21","article-title":"The increasing threat of Pseudomonas aeruginosa high-risk clones","author":"Oliver","year":"2015","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0028","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01293-19","article-title":"Synergistic meropenem\u2013tobramycin combination dosage regimens against clinical hypermutable Pseudomonas aeruginosa at simulated epithelial lining fluid concentrations in a dynamic biofilm model","volume":"63","author":"Bilal","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0029","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02203-21","article-title":"Simulated intravenous versus inhaled tobramycin with or without intravenous ceftazidime evaluated against hypermutable Pseudomonas aeruginosa via a dynamic biofilm model and mechanism-based modeling","volume":"66","author":"Bilal","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0030","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1164\/rccm.200208-855OC","article-title":"Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis","volume":"167","author":"Gibson","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0031","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1067\/mpd.2001.117785","article-title":"Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis","volume":"139","author":"Rosenfeld","year":"2001","journal-title":"J Pediatr"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0032","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40262-013-0036-y","article-title":"Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis","volume":"52","author":"Hennig","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0033","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0009-9236(99)70103-7","article-title":"Tobramycin penetration into epithelial lining fluid of patients with pneumonia","volume":"65","author":"Carcas","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0034","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/11594090-000000000-00000","article-title":"Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents","volume":"50","author":"Rodvold","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-021-01061-7","article-title":"Penetration of antibacterial agents into pulmonary epithelial lining fluid: an update","volume":"61","author":"Drwiega","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0036","unstructured":"Cystic Fibrosis Trust. Antibiotic treatment for cystic fibrosis. 3rd ed. https:\/\/www.cysticfibrosis.org.uk\/[accessed 18 February 2023]."},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0037","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/ppul.24815","article-title":"Plasma pharmacokinetics of ceftolozane\/tazobactam in pediatric patients with cystic fibrosis","volume":"55","author":"Arrieta","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0038","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1093\/jac\/dks246","article-title":"Intrapulmonary penetration of ceftolozane\/tazobactam and piperacillin\/tazobactam in healthy adult subjects","volume":"67","author":"Chandorkar","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0039","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/jamp.2011.0942","article-title":"Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin","volume":"26","author":"Ruddy","year":"2013","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0040","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.cmi.2021.05.011","article-title":"Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis","volume":"27","author":"Cortes-Lara","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0041","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1128\/AAC.01645-10","article-title":"Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study","volume":"55","author":"Cabot","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0042","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0043","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3389\/fmicb.2018.00685","article-title":"The versatile mutational resistome of Pseudomonas aeruginosa","volume":"9","author":"L\u00f3pez-Causap\u00e9","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0044","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.02462-13","article-title":"Pseudomonas aeruginosa ceftolozane\u2013tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC","volume":"58","author":"Cabot","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0045","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1128\/AAC.00727-15","article-title":"Pharmacodynamics of ceftolozane plus tazobactam studied in an in vitro pharmacokinetic model of infection","volume":"60","author":"MacGowan","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0046","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jac\/dkx424","article-title":"Mechanisms leading to in vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa","volume":"73","author":"Fraile-Ribot","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0047","doi-asserted-by":"crossref","first-page":"e02112","DOI":"10.1128\/AAC.02112-19","article-title":"Emergence of resistance to novel \u03b2-lactam\u2013\u03b2-lactamase inhibitor combinations due to horizontally acquired AmpC (FOX-4) in Pseudomonas aeruginosa sequence type 308","volume":"64","author":"Fraile-Ribot","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0048","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005932","article-title":"CpxR activates MexAB\u2013OprM efflux pump expression and enhances antibiotic resistance in both laboratory and clinical nalB-type isolates of Pseudomonas aeruginosa","volume":"12","author":"Tian","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0049","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group","volume":"340","author":"Ramsey","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0050","unstructured":"Cystic Fibrosis Foundation. Eradication of initial P. aeruginosa clinical care guidelines. https:\/\/www.cff.org\/Care\/Clinical-Care-Guidelines\/Infection-Prevention-and-Control-Clinical-Care-Guidelines\/Eradication-of-Initial-P-aeruginosa-Clinical-Care-Guidelines\/[accessed 27 June 2023]."},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0051","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jcf.2013.09.002","article-title":"Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis","volume":"13","author":"Stanojevic","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0052","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2012.06.001","article-title":"Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"12","author":"Proesmans","year":"2013","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0053","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(05)17906-9","article-title":"Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis\u2014the TOPIC study: a randomised controlled trial","volume":"365","author":"Smyth","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0054","article-title":"Aminoglycoside concentrations required for synergy with carbapenems against Pseudomonas aeruginosa determined via mechanistic studies and modeling","volume":"61","author":"Yadav","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0055","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1128\/AAC.49.2.479-487.2005","article-title":"Aminoglycoside resistance in Pseudomonas aeruginosa","volume":"49","author":"Poole","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0056","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1093\/jac\/dku151","article-title":"Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model","volume":"69","author":"Lora-Tamayo","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0057","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00078-18","article-title":"Optimization and evaluation of piperacillin\u2013tobramycin combination dosage regimens against Pseudomonas aeruginosa for patients with altered pharmacokinetics via the hollow-fiber infection model and mechanism-based modeling","volume":"62","author":"Yadav","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2020.04.034","article-title":"In pursuit of the triple crown: mechanism-based pharmacodynamic modelling for the optimization of three-drug combinations against KPC-producing Klebsiella pneumoniae","volume":"26","author":"Onufrak","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2023.106887_bib0059","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1093\/jac\/dkw293","article-title":"Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies","volume":"71","author":"Rao","year":"2016","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:45:22Z","timestamp":1760377522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923001668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0924857923001668"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106887","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceftolozane\/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106887","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106887"}}